Waldron Medical Research & Development LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$3,532	2
2023	Research	$6,432	1
2022	Research	$16,330	1
2019	Research	$16,897	6

Breakdown

Who paid Research payments · program years 2019–2025

Takeda Pharmaceuticals U.S.A., Inc. $26,294 4 payments
Array BioPharma Inc. $15,306 4 payments
Celgene Corporation $1,591 2 payments

Studies the money was for Research payments · program years 2019–2025

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (Ninlaro?) in Combination With Lenalidomide and Dexamethasone (Ird) in Patients With Multiple Myeloma Previously Receiving A Bortezomib-Based Induction Regimen (US Mm-6) $23,707 3 payments
A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600E-mutant Non-small Cell Lung Cancer $15,306 4 payments
C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) $2,588 1 payment
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) $1,050 1 payment
Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma (CC-4047-MM-007) $541 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.